Last Tuesday I watched a guy at my gym in Wesley Chapel pull a vial out of his gym bag, load a syringe in the locker room, and inject himself in the stomach. No hesitation. Like it was a protein shake. I asked him what it was. "BPC-157," he said. "For my shoulder." I asked if his doctor prescribed it. He laughed.

That interaction has been stuck in my head all week because it captures everything wrong with where peptides are right now. Here's a compound that has never been tested in a controlled human trial — not once — and people are injecting it with more confidence than I have ordering coffee. (My wife says I overthink my coffee order. She's right about that. But I'd argue under-thinking what you inject into your body is the bigger problem.)

So I spent the last three weeks pulling apart the actual research on every major peptide the biohacking world won't shut up about. Five hundred and forty-four published articles on BPC-157 alone. I read the systematic reviews, the animal studies, the one lonely human pilot study, the FDA regulatory filings, the 2024 purity analyses. And here's my honest take: most of what people believe about peptides is built on a foundation of rat studies and podcast clips. That doesn't mean peptides are useless. It means we're flying blind and pretending we can see.

Let me explain what I mean.

Peptides are short chains of amino acids, typically between 2 and 50 amino acids long. Your body makes thousands of them naturally. They're signaling molecules — tiny biological instructions that tell cells to grow, repair, release hormones, modulate inflammation. The synthetic versions in the biohacking world are either copies of natural peptides or engineered analogs designed to amplify a specific signal. The pitch sounds great: targeted biological intervention without the sledgehammer of pharmaceutical drugs. But "targeted" does not mean "tested." Those are two very different words that people keep using interchangeably.

Here's what kills me. There are peptides with genuinely strong evidence, and the biohacking community barely talks about them. Semaglutide and tirzepatide — the GLP-1 receptor agonists behind Ozempic, Wegovy, Zepbound, Mounjaro — have gone through the full gauntlet of Phase 3 randomized controlled trials. The SURMOUNT-5 trial showed tirzepatide producing 20.2% body weight loss versus 13.7% for semaglutide head-to-head. These are FDA-approved. Rigorously tested. The real deal. And they get dismissed as "Big Pharma stuff" by the same people injecting grey-market powders reconstituted from Chinese manufacturing facilities with no quality oversight. That tells you everything about the culture driving this movement.

Then there's thymosin alpha-1, which I'd argue is the most underappreciated peptide on the entire list. Over 11,000 patients across more than 30 clinical trials. FDA orphan drug status. Studied in hepatitis, immunodeficiency, and as an adjunct to cancer treatment. It was briefly placed in Category 2 by the FDA but got removed in September 2024, so it's available through compounding pharmacies again. Real human data. Real clinical foundation. And almost nobody in the biohacking world brings it up, because it's not sexy. It doesn't have a Joe Rogan endorsement. It doesn't promise to fix your torn ACL in two weeks.

PT-141, or bremelanotide, is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Actual randomized controlled trials. Actual approval. The trade-off is a 40% nausea rate, which tells you something about the cost of real clinical testing — you learn about side effects before millions of people encounter them, not after.

Cerebrolysin is a porcine-derived peptide preparation approved in Europe and Asia for traumatic brain injury and stroke recovery. Studied in over 1,900 TBI patients. Not FDA-approved here, but there's enough data that if you're dealing with a brain injury, it's worth discussing with a neurologist. If you're a healthy person hoping it'll make you smarter, though, the evidence doesn't support that use case. Wanting something to work is not the same as it working.

GHK-Cu is a copper peptide with legitimate human data — but only in topical form for skin. Multiple small trials show it promotes collagen synthesis, improves skin elasticity, and accelerates wound healing when applied to the skin. The injectable version? Category 2 by the FDA. Human evidence for systemic use is effectively zero. If you see GHK-Cu in a face serum, that's grounded in reasonable data. If someone's selling you injectable GHK-Cu for systemic anti-aging, they've outrun the science by about a decade.

Now we get to the growth hormone secretagogues — CJC-1295 and ipamorelin. These are proven to raise growth hormone levels in healthy adults. That's not disputed. The question nobody can answer yet is whether artificially jacking up your growth hormone produces the longevity and recovery benefits that proponents claim. Growth hormone has complex downstream effects. Elevated IGF-1, which rises with GH, is associated with both faster tissue repair and increased cancer risk. That's not a typo. The same mechanism that helps you heal may also feed tumors. Both were removed from Category 2 in September 2024 and are available via compounding pharmacies. If you go this route, regular IGF-1 monitoring through blood work is non-negotiable. Period.

Selank and semax are approved in Russia for anxiety and cognitive enhancement, respectively. The research is almost entirely in Russian-language journals, which makes independent verification a nightmare for English-speaking clinicians. The mechanisms are interesting — selank modulates GABA and serotonin, semax acts on BDNF — but the evidence doesn't meet Western clinical standards. Not junk science. Not proven science either. Somewhere in a grey zone that makes me uncomfortable recommending them.

And then there's BPC-157. The darling. The one everyone asks about. Five hundred forty-four published articles sounds impressive until you realize only one is a clinical trial in humans, and it was a small pilot study. Everything else? Rats. The animal data is genuinely remarkable — I'll give it that. BPC-157 accelerates tendon, ligament, muscle, and gut healing in rodent models with a consistency that is unusual for preclinical research. Peter Attia has said he used it after surgery. Rogan praises it constantly. But a 2024 systematic review by Vasireddi et al. in the American Journal of Sports Medicine looked at every available BPC-157 study and landed exactly where you'd expect: extensive animal evidence, near-zero human evidence, no clinical recommendations possible. That's not me being pessimistic. That's the researchers who actually reviewed all 544 papers telling you the same thing.

BPC-157 is currently in Category 2 — banned from compounding — though the RFK Jr. reclassification announced February 27, 2026, is expected to move approximately 14 peptides, including BPC-157, back to Category 1. I want to be crystal clear about something: reclassification is a regulatory access decision. It is not a safety endorsement. It does not conjure evidence that didn't exist last month.

Epithalon activates telomerase in cell culture. Sounds exciting until you remember that cancer cells also activate telomerase — it's literally one of the hallmarks of cancer. There's a process called ALT (alternative lengthening of telomeres) that cancer cells exploit. The human studies are limited to small Russian trials. The risk-reward calculus here makes me deeply uneasy.

TB-500 — and I need to say this plainly — has zero human studies. None. Zero. There is Phase 2 clinical data on its parent compound, thymosin beta-4, but TB-500 is a fragment of that molecule. Not the same thing. People are injecting a compound that has literally never been studied in a human being in any context, and treating anecdotal reports on Reddit as if they're peer-reviewed evidence. They are not.

Then there's AOD-9604, which completed a Phase IIb clinical trial for fat loss and... didn't work. It was safe, sure. It just didn't produce meaningful fat loss compared to placebo. It was removed from Category 2 in September 2024, so you can still buy it. But spending money on a peptide that has already failed its own clinical trial feels like a special kind of optimism I can't relate to.

I haven't even gotten to the sourcing problem, which honestly scares me more than the evidence gaps. A 2024 analysis of online "semaglutide" — a peptide that is FDA-approved, well-characterized, and widely available through legitimate pharmacies — found purity levels as low as 7 to 14%. Seven percent. If quality control is that catastrophic for a famous, regulated peptide, what do you think the grey-market BPC-157 in that guy's gym bag looks like? Broader testing found that up to 40% of peptides sold online contained incorrect dosages or undeclared ingredients. Two women were hospitalized after receiving peptide injections at a longevity conference in 2025. This isn't hypothetical risk. This is people ending up in emergency rooms.

Compounding pharmacies offer better quality assurance than direct-to-consumer online purchases, but they're not held to the same manufacturing standards as pharmaceutical companies. A third-party certificate of analysis is the bare minimum due diligence. Most buyers never ask for one. If your vendor can't provide a COA showing identity, purity, and endotoxin testing, walk away. That refusal tells you everything.

There's a cancer question hanging over all of this that the peptide-enthusiast community hand-waves away far too quickly. BPC-157 and TB-500 both promote angiogenesis — the growth of new blood vessels. That's the mechanism by which they theoretically accelerate tissue healing. It's also one of the primary mechanisms cancers use to grow and metastasize. Tumors need blood supply. Anything that promotes blood vessel growth could, in theory, feed a dormant or undetected tumor. Andrew Huberman has flagged this concern publicly. Peter Attia has acknowledged it. The risk is theoretical — there are no human studies showing BPC-157 causes cancer — but it is mechanistically plausible. If you have a personal or family history of cancer, that theoretical risk carries real weight. Epithalon raises a parallel concern through telomerase activation. None of this means these peptides definitely cause cancer. It means we don't know, and the biology gives us reason to take the question seriously instead of shrugging it off.

So here's where I land, and I'm going to be direct about it: most peptides are overhyped. BPC-157 is interesting but unproven in humans. And if you're spending money on grey-market peptides before you've nailed the proven basics, you're doing this backwards.

I know that's not what the internet wants to hear. I know it's less exciting than "here's my peptide stack." But look at the actual hierarchy of evidence. Collagen peptides — yes, they're peptides — have real human RCT data supporting joint and skin health at 10 to 15 grams per day. Creatine monohydrate has decades of human evidence for recovery and performance. Quality sleep, resistance training, and adequate protein intake do more for tissue repair than any grey-market vial. Thorne makes third-party tested versions of both collagen and creatine, NSF Certified for Sport — readers get 10% off through that link. If you're going to spend money on recovery, start with the compounds that actually have human data behind them. That's not boring advice. That's honest advice. Vital Proteins Collagen Peptides is one of the most popular and well-reviewed options on Amazon if you want to start there.

If you still want to explore peptides after that foundation is locked in, here's the responsible path. Talk to your doctor about GLP-1 receptor agonists if you have a clinical indication. Look into thymosin alpha-1, which has the strongest evidence base of any non-GLP-1 peptide. If BPC-157 is calling your name, use a reputable compounding pharmacy, demand a COA, and work with a physician who can monitor for adverse effects. For topical applications, GHK-Cu in skin serums has reasonable evidence and is available over the counter — that's the lowest-risk way to experiment with peptide science.

One more thing worth knowing. The FDA's crackdown on peptide compounding in 2024 pushed the market underground, which paradoxically made sourcing less safe. Category 2 restrictions eliminated regulated compounding pharmacy access, driving buyers to unregulated online vendors with zero quality oversight. Meanwhile, oral peptide delivery technology is advancing — Novo Nordisk's oral semaglutide (Rybelsus) uses a specialized absorption enhancer to achieve usable bioavailability — but that technology hasn't been applied to BPC-157 or other biohacking peptides yet. And on the topic of oral delivery: most peptides have oral bioavailability below 1%. Stomach acid destroys them before they reach the bloodstream. If someone's selling you oral BPC-157 capsules and claiming systemic effects, basic pharmacokinetics says no. Oral BPC-157 may have local effects in the GI tract — that's where the one human pilot study focused — but systemic delivery requires injection or intranasal administration.

The regulatory picture as of March 2026: three peptides are FDA-approved by prescription (semaglutide, tirzepatide, bremelanotide). Five were removed from Category 2 in September 2024 and are available via compounding pharmacies (AOD-9604, CJC-1295, ipamorelin acetate, thymosin alpha-1, selank acetate). And roughly 14 more, including BPC-157, TB-500, epithalon, LL-37, DSIP, and injectable GHK-Cu, are currently banned from compounding but expected to move to Category 1 under the RFK Jr. reclassification. Again — that's an access decision, not a verdict on safety or efficacy.

I keep coming back to something Peter Attia said about peptides. He's cautiously skeptical. He's used BPC-157 himself but won't recommend peptides as general longevity tools. Huberman calls the peptide space "the wild west" and specifically warns about the cancer risk from angiogenesis-promoting compounds. Dr. Eric Topol is blunt: "None of these peptides are proven." Bryan Johnson includes them in his Blueprint protocol, but Johnson represents the most aggressive end of the self-experimentation spectrum — most of us don't have his monitoring infrastructure or his tolerance for unknowns.

The responsible middle ground is this: the animal data for BPC-157 is genuinely interesting and warrants human trials. But "warrants human trials" and "safe and effective for you to inject right now" are separated by years of research that hasn't been done. Acknowledging that gap isn't being anti-peptide. It's being honest about where the science actually stands versus where we wish it stood.

So here's my question for you: if the evidence is this thin, why are so many smart people so confident about peptides? Is it because the anecdotal reports are that compelling — or because we want them to be?

Disclosure: Product links above may be affiliate links. I only recommend products I would personally use and would recommend regardless of compensation.